medigraphic.com
Instituto Nacional de Salud Pública

2024, Number 6

<< Back Next >>

salud publica mex 2024; 66 (6)

Kidney disease in Mexican patients with type 2 diabetes mellitus and their sociodemographic characteristics

Gutiérrez-Alba G, Montero-Mora JG, Gutiérrez-Polo R, Ramírez-Cabrera JB, Castro-Miranda B

Language: Spanish
References: 37
Page: 788-797
PDF size: 370.10 Kb.


ABSTRACT

Objective. To determine in patients without social security with type 2 diabetes mellitus the prevalence of kidney disease (KD), their clinical and sociodemographic characteristics. Materials and methods. Cross-sectional and analytical study. 980 patients without a diagnosis of KD from 86 health centers participated. For the association of KD with other variables, the Fisher test and the Pearson χ2 test were used; Also, a multiple ordinal logistic regression model was fitted. Results. The prevalence of KD was 53%, stage 2 with 33.98% and 2.76% for stages 4-5. Furthermore, 75% of patients have glycated hemoglobin ≥6.5 and multiple comorbidities. The factors associated with KD were age, proteinuria, and consumption of nonsteroidal anti-inflammatory drugs. Conclusions. The challenge of the health system is to improve the skills of health personnel to control non-communicable diseases, make early diagnosis and provide care by stage of KD.


REFERENCES

  1. International Diabetes Federation. Facts & figures. IDF, 2021 [citado ago 22, 2023]. Disponible en: https://idf.org/about-diabetes/facts-figures/

  2. Gobierno de México. En México, 12.4 millones de personas viven condiabetes. México: SS, 2022 [Internet] [citado abr 14, 2023]. Disponibleen: https://www.gob.mx/salud/prensa/547-en-mexico-12-4-millones-depersonas-viven-con-diabetes?idiom=es

  3. Organización Panamericana de la Salud, Organización Mundial de laSalud. La OPS/OMS y la Sociedad Latinoamericana de Nefrología llamana prevenir la enfermedad renal y a mejorar el acceso al tratamiento.OPS/OMS, 2015 [Internet] [citado abr 10, 2023]. Disponible en: https://www3.paho.org/hq/index.php?option=com_content&view=article&id=10542:2015-opsoms-sociedad-latinoamericana-nefrologia-enfermedadrenal-mejorar tratamiento&Itemid=0&lang=es#gsc.tab=0

  4. Villegas LE, Buriticá M, Yepes CE, Montoya YM, Jaimes F. Interacción entreel estadio de la enfermedad renal crónica y la diabetes mellitus comofactores asociados con mortalidad en pacientes con enfermedad renalcrónica: un estudio de cohortes externas. Nefrologia. 2022;42(5):501-620.https://doi.org/10.1016/j.nefro.2021.04.012

  5. Fernández-Fernández L, Goujat-Salas J, Ceballos-Malagón C, Tejero-MasM, Pérez-Caballero FL, Buitrago-Ramírez F. Prevalence by health areas ofchronic kidney disease in the diabetic population of Extremadura in 2012,2013 and 2014. An observational study. Nefrologia. 2022;42(6):704-13.https://doi.org/10.1016/j.nefroe.2023.02.005

  6. Simões AC, Miranda AS, Rocha NP, Teixeira AL. Neuropsychiatric disordersin chronic kidney disease. Front Pharmacol. 2019;16(10):932. https://doi.org/10.3389/fphar.2019.00932

  7. Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney diseaseand the sustainable development goals. Bull World Health Organ.2018;96(6):414-22. https://doi.org/10.2471/BLT.17.206441

  8. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaugheyM, et al. Forecasting life expectancy, years of life lost, and all-cause andcause-specific mortality for 250 causes of death: Reference and alternativescenarios for 2016-40 for 195 countries and territories. Lancet.2018;392(10159):2052-90. https://doi.org//10.1016/S0140-6736(18)31694-5

  9. Elshahat S, Cockwell P, Maxwell AP, Griffin M, O’Brien T, O’Neill C.The impact of chronic kidney disease on developed countries from ahealth economics perspective: A systematic scoping review. PLoS ONE.2020;15(3):e0230512. https://doi.org/10.1371/journal.pone.0230512

  10. Wang JS, Yen FS, Lin KD, Shin SJ, Hsu YH, Hsu CC. Epidemiologicalcharacteristics of diabetic kidney disease in Taiwan. J Diabetes Investig.2021;12(12):2112-23. https://doi.org/10.1111/jdi.13668

  11. Pöhlmann J, Bergenheim K, Garcia-Sanchez JJ, Rao N, Briggs A, PollockRF. Modeling chronic kidney disease in type 2 diabetes mellitus: a systematicliterature review of models, data sources, and derivation cohorts.Diabetes Ther. 2022;13(4):651-77. https://doi.org/10.1007/s13300-022-01208-0

  12. Villarreal E, Padilla R, Vargas ER, Martínez L, Galicia L. Costo por estadiode la atención integral del paciente diabético tipo 2 con enfermedadrenal crónica. Physis. 2017;27(04):1125-46. https://doi.org/10.1590/S0103-73312017000400014

  13. Tamayo JA, Lastiri HS. La enfermedad renal crónica en México. Haciauna política nacional para enfrentarla. México: InterSistemas, 2016.

  14. Scheaffer RL, Mendenhall W, Ott RL. Elementos de muestreo. 6ta ed.Madrid: Paraninfo, 2006.

  15. National Kidney Foundation. CKD-EPI Creatinine Equation (2021).NKF, 2023 [Internet] [citado abr 28, 2023]. Disponible en: https://www.kidney.org/content/ckd-epi-creatinine-equation-2021

  16. Cliff, N. Ordinal methods for behavioral data analysis. Psychology Press.1996. https://doi.org/10.4324/9781315806730

  17. R Core Team. R: The R Project for Statistical Computing. R-project.org. 2022 [Internet] [citado may 4, 2023]. Disponible en: https://www.rproject.org/

  18. Joshi R, Subedi P, Yadav GK, Khadka S, Rijal T, Amgain K, RajbhandariS. Prevalence and risk factors of chronic kidney disease among patientswith type 2 diabetes mellitus at a tertiary care hospital in Nepal: a crosssectionalstudy. BMJ Open. 2023;13(2):e067238. https://doi.org/10.1136/bmjopen-2022-067238

  19. Metsärinne K, Bröijersen A, Kantola I, Niskanen L, Rissanen A,Appelroth T, et al. High prevalence of chronic kidney disease in Finnishpatients with type 2 diabetes treated in primary care. Prim Care Diabetes.

  20. 2015;9(1):31-8. https://doi.org/10.1016/j.pcd.2014.06.00120. Lamine F, Lalubin F, Pitteloud N, Burnier M, Zanchi A. Chronic kidneydisease in type 2 diabetic patients followed-up by primary care physiciansin Switzerland: prevalence and prescription of antidiabetic drugs. SwissMed Wkly. 2016;146:w14282. https://doi.org/10.4414/smw.2016.14282

  21. Wu B, Bell K, Stanford A, Kern DM, Tunceli O, Vupputuri S. UnderstandingCKD among patients with T2DM: prevalence, temporal trends, andtreatment patterns-NHANES 2007-2012. BMJ Open Diabetes Res Care.2016;4(1):e000154. https://doi.org/10.1136/bmjdrc-2015-000154

  22. Martínez J, Sangrós J, García FJ, Millaruelo JM, Díez J, Bordonaba D, etal. Enfermedad renal crónica en España: prevalencia y factores relacionadosen personas con diabetes mellitus mayores de 64 años. Nefrologia.2018;38(4):401-13. https://doi.org/10.1016/j.nefro.2017.11.025

  23. Coll-de-Tuero G, Mata-Cases M, Rodriguez-Poncelas A, Pepió JM,Roura P, Benito B. Chronic kidney disease in the type 2 diabetic patients:prevalence and associated variables in a random sample of 2642patients of a Mediterranean area. BMC Nephrol. 2012;13:87. https://doi.org/10.1186/1471-2369-13-87

  24. Cha’on U, Tippayawat P, Sae-ung N, Pinlaor P, Sirithanaphol W, TheeranutA, et al. High prevalence of chronic kidney disease and its relatedrisk factors in rural areas of Northeast Thailand. Sci Rep. 2022;12:18188.https://doi.org/10.1038/s41598-022-22538-w

  25. Castañeda L, Losada LM, Serna J, Duque J, Nieto OA. Prevalencia de laenfermedad renal crónica en pacientes con diabetes mellitus tipo 2 de unprograma de riesgo cardiovascular. Rev. Colomb. Nefrol. 2020;7(2):55-66.https://doi.org/10.22265/acnef.7.2.481

  26. Nazzal Z, Hamdan Z, Masri D, Abu-Kaf O, Hamad M. Prevalence andrisk factors of chronic kidney disease among Palestinian type 2 diabeticpatients: a cross-sectional study. BMC Nephrol. 2020;21(1):484. https://doi.org/10.1186/s12882-020-02138-4

  27. Obrador GT, García-García G, Villa AR, Rubilar X, Olvera N, Ferreira E,et al. Prevalence of chronic kidney disease in the Kidney Early EvaluationProgram (KEEP) México and comparison with KEEP US. Kidney Int Suppl.2010;77(116):S2-8. https://doi.org/10.1038/ki.2009.540

  28. Chu L, Fuller M, Jervis K, Ciaccia A, Abitbol A. Prevalence of chronickidney disease in type 2 diabetes: the Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study. Clin Ther. 2021;43(9):1558-73. https://doi.org/10.1016/j.clinthera.2021.07.015

  29. Duan J, Wang C, Liu D, Qiao Y, Pan S, Jiang D, et al. Prevalence and riskfactors of chronic kidney disease and diabetic kidney disease in Chineserural residents: a cross-sectional survey. Sci Rep. 2019;9(1):10408. https://doi.org/10.1038/s41598-019-46857-7

  30. Yang Y, Wang N, Jiang Y, Zhao Q, Chen Y, Ying X. The prevalence ofdiabetes mellitus with chronic kidney disease in adults and associatedfactors in Songjiang District, Shanghai. Ann Palliat Med. 2021;10(7):7214-24. https://doi.org/10.21037/apm-21-803

  31. García-Trabanino R, Cerdas M, Madero M, Jakobsson K, Barnoya J,Crowe J, et al. Nefropatía mesoamericana: revisión breve basada en elsegundo taller del Consorcio para el estudio de la Epidemia de Nefropatíaen Centroamérica y México (CENCAM). Nefrol Latinoam. 2017;14(1):39-45. https://doi.org/10.1016/j.nefrol.2016.11.001

  32. Aguilar DJ, Madero M. Other potential CKD hotspots in the world: thecases of Mexico and the United States. Semin Nephrol. 2019;39(3):300-7.https://doi.org/10.1016/j.semnephrol.2019.02.008

  33. Bharati J, Zavaleta-Cortijo C, Bressan T, Shingada A, ObradorG, Sola L, et al. The environment and kidney health: challenges andopportunities. Salud Publica Mex. 2022;64(supl 1):S46-55. https://doi.org/10.21149/12799

  34. Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosisand management: a review. JAMA. 2019;322(13):1294-304. https://doi.org/10.1001/jama.2019.14745

  35. Swaminathan SM, Rao IR, Shenoy SV, Prabhu AR, Mohan PB, Rangaswamy D, et al. Novel biomarkers for prognosticating diabetic kidneydisease progression. Int Urol Nephrol. 2023;55(4):913-28. https://doi.org/10.1007/s11255-022-03354-7

  36. Campos-Nonato I, Galván-Valencia O, Hernández-Barrera L,Oviedo-Solís C, Barquera S. Prevalencia de obesidad y factores deriesgo asociados en adultos mexicanos: resultados de la Ensanut2022. Salud Publica Mex. 2023;65(supl 1):S238-47. https://doi.org/10.21149/14809

  37. Cortés-Valencia A, Ortiz-Rodríguez S, Balderas-Arteaga N, CatzinKuhlmann A, Correa-Rotter R, González-Villalpando C, et al. TheMexican Consortium of Epidemiological Studies for the Prevention,Diagnosis, and Treatment of Chronic Kidney Disease: a review ofcollaborating studies. Salud Publica Mex. 2022;64(4):434-42. https://doi.org/10.21149/13101




2020     |     www.medigraphic.com